Melanoma vaccine: final tests on Moderna’s mRNA in combination with immunotherapy
Source: Breaking Latest News, July 2023
The final phase of clinical trials of Moderna’s V940 anti-melanoma vaccine is underway, in combination with Merck’s Keytruda immunotherapy.
The V940 (mRna-4157) melanoma vaccine developed by Moderna, based on messenger RNA (mRNA) technology, has reached the final stage of clinical trials. This vaccine is combined with Merck’s pembrolizumab (Keytruda*) immunotherapy, and has been tested as an adjuvant treatment in patients with resected high-risk melanoma, including those with stage IIB-IV disease.
The Phase 3 trial of the vaccine candidate, called V940-001, has begun patient recruitment in Australia, involving more than 165 centers in more than 25 countries and aiming to enroll approximately 1,089 participants. The trial will be double-blind randomized, meaning that both patients and healthcare professionals involved will not know whether they are receiving the investigational personalized neoantigenic mRNA vaccine V940 in combination with immunotherapy or immunotherapy alone.